




aln collaboration with Medlmmune Limited, a wholly owned subsidiary of AstraZeneca PLC. AstraZeneca Pln collaboration with bluebird bio, Inc. bluebirdbio of Inc. ollaboration with Acceleron Pharma, Inc. Acceleron Pharma, Inc. ollaboration with Agios Pharmaceuticals, Inc. ogios

REVLIMID®, POMALYST®, IMNOVID®, THALOMID®, Thalidomide Celgene®, and VIDAZA® are registered trademarks of Celgene Corporation.

For information on approved uses, please refer to approved product labeling. Post-approval research includes Celgene-sponsored and Celgene-supported studies.

^{*&#}x27;Regulatory submission' indicates US and/or EU submission unless other country/region is indicated under Area of Research.





^aFiling for regulatory approval based on pivotal phase II data. ^bIn collaboration with MedImmune Limited, a wholly owned subsidiary of AstraZeneca PLC. Ast

^cIn collaboration with Juno Therapeutics. [†] Celgene has commercial rights outside of North America and China.

din collaboration with Acceleron Pharma, Inc. Acceleron

REVLIMID® and ISTODAX® are registered trademarks of Celgene Corporation.

	Area of Research	Phase 1	Phase 2	Phase 3	Post-Approval Research
SOLID TUMORS					
ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) (US)/ (paclitaxel formulated as albumin-bound nanoparticles) (EU)	Breast: Metastatic				
	Non-small cell lung: Advanced (first-line)				
	Pancreatic: Metastatic (first-line)				
	Pancreatic: Adjuvant				
	Gastric: Metastatic (Japan) ^a				
CC-486	Breast: Metastatic				
	Non-small cell lung: Advanced				
Marizomib	Glioblastoma				
CC-122	Hepatocellular carcinoma				
Anti-CD47 Antibody: CC-90002					
Pan-IDH Inhibitor: AG-881 ^b	Glioma				
LSD1 Inhibitor: CC-90011					



^aTrial conducted by licensee partner, Taiho Pharmaceuticals Co. Ltd. ^bIn collaboration with Agios Pharmaceuticals, Inc. — agios ABRAXANE® is a registered trademark of Celgene Corporation.

